LTC0914118I2 - Pakeistieji 3,5-difenil-1,2,4-triazolai ir jų panaudojimas farmaciniais metalų chelatoriais - Google Patents

Pakeistieji 3,5-difenil-1,2,4-triazolai ir jų panaudojimas farmaciniais metalų chelatoriais

Info

Publication number
LTC0914118I2
LTC0914118I2 LTPA2007001C LTPA2007001C LTC0914118I2 LT C0914118 I2 LTC0914118 I2 LT C0914118I2 LT PA2007001 C LTPA2007001 C LT PA2007001C LT PA2007001 C LTPA2007001 C LT PA2007001C LT C0914118 I2 LTC0914118 I2 LT C0914118I2
Authority
LT
Lithuania
Prior art keywords
triazoles
diphenyl
modified
metal chelators
pharmaceutical metal
Prior art date
Application number
LTPA2007001C
Other languages
English (en)
Lithuanian (lt)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=4214048&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LTC0914118(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of LTPA2007001I1 publication Critical patent/LTPA2007001I1/lt
Publication of LTC0914118I2 publication Critical patent/LTC0914118I2/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/04—Chelating agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
LTPA2007001C 1996-06-25 2007-01-16 Pakeistieji 3,5-difenil-1,2,4-triazolai ir jų panaudojimas farmaciniais metalų chelatoriais LTC0914118I2 (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH159396 1996-06-25
PCT/EP1997/003315 WO1997049395A1 (en) 1996-06-25 1997-06-24 Substituted 3,5-diphenyl-1,2,4-triazoles and their use as pharmaceutical metal chelators

Publications (2)

Publication Number Publication Date
LTPA2007001I1 LTPA2007001I1 (lt) 2018-06-25
LTC0914118I2 true LTC0914118I2 (lt) 2018-12-27

Family

ID=4214048

Family Applications (1)

Application Number Title Priority Date Filing Date
LTPA2007001C LTC0914118I2 (lt) 1996-06-25 2007-01-16 Pakeistieji 3,5-difenil-1,2,4-triazolai ir jų panaudojimas farmaciniais metalų chelatoriais

Country Status (36)

Country Link
US (3) US6465504B1 (forum.php)
EP (1) EP0914118B1 (forum.php)
JP (1) JP3541042B2 (forum.php)
KR (1) KR100616378B1 (forum.php)
CN (1) CN1146415C (forum.php)
AP (1) AP1127A (forum.php)
AR (1) AR007479A1 (forum.php)
AT (1) ATE226435T1 (forum.php)
AU (1) AU718037B2 (forum.php)
BG (1) BG64248B1 (forum.php)
BR (1) BR9709973A (forum.php)
CA (1) CA2255951C (forum.php)
CY (2) CY2429B1 (forum.php)
CZ (1) CZ291470B6 (forum.php)
DE (3) DE122007000020I1 (forum.php)
DK (1) DK0914118T3 (forum.php)
ES (1) ES2187785T3 (forum.php)
FR (1) FR06C0049I2 (forum.php)
GE (1) GEP20084355B (forum.php)
HU (1) HU226232B1 (forum.php)
IL (1) IL127212A0 (forum.php)
LT (1) LTC0914118I2 (forum.php)
LU (1) LU91291I2 (forum.php)
MY (1) MY129541A (forum.php)
NL (1) NL300248I2 (forum.php)
NO (3) NO317180B1 (forum.php)
NZ (1) NZ333308A (forum.php)
OA (1) OA10946A (forum.php)
PL (1) PL194758B1 (forum.php)
PT (1) PT914118E (forum.php)
RU (1) RU2208010C2 (forum.php)
SI (1) SI0914118T1 (forum.php)
SK (1) SK284319B6 (forum.php)
TR (1) TR199802693T2 (forum.php)
TW (1) TW533205B (forum.php)
WO (1) WO1997049395A1 (forum.php)

Families Citing this family (109)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6677487B2 (en) 2001-08-30 2004-01-13 Pharmacia Corporation α-haloenamine reagents
GB0126618D0 (en) * 2001-11-06 2002-01-02 Novartis Ag Organic compounds
ES2192494B1 (es) * 2002-03-27 2005-02-16 Consejo Superior De Investigaciones Cientificas Derivados de 1,2,4-triazol con propiedades cannabinoides.
US8829198B2 (en) * 2007-10-31 2014-09-09 Proteotech Inc Compounds, compositions and methods for the treatment of beta-amyloid diseases and synucleinopathies
GB0223978D0 (en) * 2002-10-15 2002-11-20 Novartis Ag Organic compound
MY142651A (en) * 2003-03-18 2010-12-15 Merck Sharp & Dohme Biaryl substituted triazoles as sodium channel blockers
US20090227647A1 (en) 2008-03-05 2009-09-10 Thomas Lake Compounds, Compositions and Methods for the Treatment of Islet Amyloid Polypeptide (IAPP) Accumulation in Diabetes
US20050008699A1 (en) * 2003-07-11 2005-01-13 Fred Wehling Effervescent glucosamine composition
BRPI0416319A (pt) * 2003-11-10 2007-01-09 Merck & Co Inc composto, composição farmacêutica, métodos de tratamento ou prevenção da dor, das sìndromes, e de doença, e, métodos de administrar anestesia local, e para a neuroproteção sob condições isquêmicas
KR20060125810A (ko) * 2003-12-19 2006-12-06 노파르티스 아게 （ａ）엔-〔5-［4-（4-메틸-피페라지노-메틸）-벤조일아미도］-2메틸페닐〕-4-（3-피리딜）-2-피리미딘-아민 및（ｂ） 1종 이상의 하이퓨지네이션 억제제의 조합물 및그의 용도
GB0408078D0 (en) * 2004-04-08 2004-05-12 Novartis Ag Organic compounds
EP1755579A4 (en) * 2004-05-24 2009-06-10 Univ New York METHOD OF TREATING OR PREVENTING PATHOLOGICAL EFFECTS OF ACUTE INCREASES IN HYPERGLYCEMIA AND / OR ACUTE INCREASES OF FREE FATTY ACID FLOWS
US9737511B2 (en) * 2004-05-24 2017-08-22 Geoffrey C. GURTNER Method of treating or preventing pathologic effects of acute increases in hyperglycemia and/or acute increases of free fatty acid flux
ES2373912T3 (es) * 2005-01-28 2012-02-10 Novartis Ag Uso de pirimidilaminobenzamidas para el tratamiento de enfermedades que responden a la modulación de la actividad de quinasa tie-2.
US20080187510A1 (en) * 2005-02-10 2008-08-07 Camenisch Gian P Methods for Improving Drug Disposition
KR20080003933A (ko) * 2005-05-31 2008-01-08 노파르티스 아게 철이 발병에 관여하는 간질환의 치료
AU2006303514B2 (en) * 2005-10-19 2010-06-24 Novartis Ag Dispersible tablets comprising deferasirox
JP5322651B2 (ja) * 2005-11-01 2013-10-23 ノバルティス アーゲー シンチグラフィー法
EP1988083B1 (en) * 2006-02-03 2014-04-02 Taisho Pharmaceutical Co., Ltd. Triazole derivative
CA2649792A1 (en) * 2006-05-09 2007-11-15 Novartis Ag Combination comprising an iron chelator and an anti-neoplastic agent and use thereof
DK2026801T3 (da) * 2006-05-23 2014-01-27 Novartis Ag Deferasirox til behandling af arvelig hæmochromatose
TWI448285B (zh) * 2006-07-13 2014-08-11 Los Angeles Biomed Res Inst 用以治療白黴菌症（ｍｕｃｏｒｍｙｃｏｓｉｓ）及其他真菌類疾病之組合物及方法
MX2009001290A (es) * 2006-08-04 2009-02-11 Novartis Ag Tratamiento de disfusion endocrina utilizando quelantes de hierro.
RU2339625C2 (ru) * 2006-11-02 2008-11-27 Российский химико-технологический университет (РХТУ им. Д.И. Менделеева) ЗАМЕЩЕННЫЕ N-[ω-АЗОЛ-1-ИЛ)АЛКИЛ]БЕНЗОЛСУЛЬФАМИДЫ В КАЧЕСТВЕ СРЕДСТВ С АНТИАГРЕГАЦИОННОЙ АКТИВНОСТЬЮ И СПОСОБЫ ИХ ПОЛУЧЕНИЯ
KR20150046369A (ko) * 2006-11-29 2015-04-29 노파르티스 아게 데페라시록스 (ｉｃｌ６７０ａ)의 다형체 형태
EP1927591A1 (en) * 2006-11-29 2008-06-04 Novartis AG Polymorphic Forms of Deferasirox (ICL670)
WO2008094617A2 (en) * 2007-01-29 2008-08-07 Teva Gyógyszergyár Zártkörüen Müködö Részvénytársaság Crystalline forms of deferasirox
MX2009012375A (es) * 2007-05-14 2009-12-01 Novartis Ag Uso de quelante del hierro para el tratamiento del infarto de miocardio.
EP1994930A1 (en) 2007-05-22 2008-11-26 Novartis AG Triazol compounds for treating biofilm formation
WO2009016359A1 (en) * 2007-07-27 2009-02-05 Pliva Hrvatska D.O.O. New forms of deferasirox
US20090082412A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched deferasirox
WO2009067557A1 (en) 2007-11-19 2009-05-28 Teva Pharmaceutical Industries Ltd. Deferasirox pharmaceutical compositions
CZ301873B6 (cs) 2008-01-30 2010-07-14 Farmak, A. S. Zpusob prípravy kyseliny 4-[3,5-bis(2-hydroxyfenyl)-[1,2,4]triazol-1-yl]benzoové
WO2009106824A2 (en) * 2008-02-25 2009-09-03 Cipla Limited Pharmaceutical formulations
US20110097413A1 (en) * 2008-04-21 2011-04-28 Actavis Group Ptc Ehf Solid state forms of deferasirox salts and process for the preparation thereof
US20110171138A1 (en) * 2008-06-02 2011-07-14 Actavis Group Ptc Ehf Substantially pure deferasirox and processes for the preparation thereof
WO2010032489A1 (ja) 2008-09-22 2010-03-25 国立大学法人旭川医科大学 鉄キレート剤及びその製造方法、並びに鉄イオンの定量・捕捉方法
US10098857B2 (en) 2008-10-10 2018-10-16 The Board Of Trustees Of The Leland Stanford Junior University Topical and transdermal delivery of HIF-1 modulators to prevent and treat chronic wounds
WO2010092419A1 (en) 2009-02-12 2010-08-19 Assistance Publique - Hopitaux De Paris Combined treatment of multiple sclerosis
EP2408804A4 (en) 2009-03-19 2012-10-03 Los Angeles Biomed Res Inst VACCINE COMPOSITIONS AND METHODS FOR THE TREATMENT OF MUCORMYCOSIS AND OTHER FUNGAL DISEASES
IT1398770B1 (it) * 2009-07-22 2013-03-18 Bellacchio Oligonucleotidi attivabili mediante l'appaiamento con sequenze di acidi nucleici e loro uso
WO2011021218A2 (en) * 2009-08-12 2011-02-24 Msn Laboratories Limited Process for the preparation of 4-[3,5-bis(2-hydroxyphenyl)-1h-1,2,4-triazol-1-yl]-benzoic acid and its amine salts
CA2781821A1 (en) 2009-12-07 2011-06-16 Mapi Pharma Limited Processes for the preparation of deferasirox, and deferasirox polymorphs
EP2590630B1 (en) 2010-07-08 2015-04-29 ratiopharm GmbH Oral dosage form of deferasirox
US8907083B2 (en) 2010-08-25 2014-12-09 Ramamohan Rao Davuluri Process for the preparation, of 2-(2-hydroxyphenyl)-benz [1, 3] oxazin-4-one and its use for preparation of 4-[3, 5-bis (2-hydroxyphenyl)-IH-I, 2, 4-triazolTI-yl] benzoic acid
PE20140166A1 (es) * 2010-10-01 2014-02-17 Cipla Ltd Composicion farmaceutica que comprende deferasirox
US9018389B2 (en) 2010-11-24 2015-04-28 Alembic Pharmaceuticals, Ltd. Process for the preparation of Deferasirox
US9796605B2 (en) 2011-01-14 2017-10-24 Disease Adsorption System Technologies Co., Ltd. Polymeric iron chelating agent
WO2013053904A1 (en) 2011-10-14 2013-04-18 Photocure Asa Stent
US20140276107A1 (en) 2011-10-14 2014-09-18 Photocure Asa Photodynamic diagnosis
US8822464B2 (en) 2011-11-28 2014-09-02 Boehringer Ingelheim International Gmbh N-aryl-piperazine derivatives and their use as positive allosteric modulators of mGluR5 receptors
US8741892B2 (en) 2011-12-05 2014-06-03 Boehringer Ingelheim International Gmbh Compounds
US8642774B2 (en) 2011-12-08 2014-02-04 Boehringer Ingelheim International Gmbh Compounds
US8846948B2 (en) 2011-12-13 2014-09-30 Boehringer Ingelheim International Gmbh Compounds
US8796467B2 (en) 2011-12-13 2014-08-05 Boehringer Ingelheim International Gmbh Compounds
US8937176B2 (en) 2011-12-14 2015-01-20 Boehringer Ingelheim International Gmbh Compounds
US8716277B2 (en) 2011-12-14 2014-05-06 Boehringer Ingelheim International Gmbh Substituted imidazole compounds useful as positive allosteric modulators of mGlu5 receptor activity
US8883789B2 (en) 2011-12-14 2014-11-11 Boehringer Ingelheim International Gmbh Piperazine derivatives and their use as positive allosteric modulators of mGluR5 receptors
US8889677B2 (en) * 2012-01-17 2014-11-18 Boehringer Ingellheim International GmbH Substituted triazoles useful as mGlu5 receptor modulators
US9593086B2 (en) * 2013-03-06 2017-03-14 Biocon Limited Process for the preparation of deferasirox
JP6434429B2 (ja) * 2013-03-08 2018-12-05 ノバルティス アーゲー デフェラシロクスの経口製剤
PE20151934A1 (es) * 2013-05-10 2015-12-26 Cipla Ltd Composicion farmaceutica de dosis baja
DE102013217390A1 (de) 2013-09-02 2015-03-05 Henkel Ag & Co. Kgaa Wasch- und Reinigungsmittel mit verbesserter Leistung
CN103454370B (zh) * 2013-09-11 2014-12-24 中美华世通生物医药科技（武汉）有限公司 一种利用hplc测定原料药中苯肼类化合物残留的方法
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
JP6576962B2 (ja) 2014-03-14 2019-09-18 ノバルティス アーゲー Ｌａｇ−３に対する抗体分子およびその使用
PL2946771T3 (pl) 2014-05-20 2019-10-31 Sanovel Ilac Sanayi Ve Ticaret As Preparat w postaci dyspergowalnej w wodzie tabletki zawierający deferazyroks
EP2987482A1 (en) 2014-08-22 2016-02-24 Santa Farma Ilaç Sanayi A.S. Soluble and dispersible pharamaceutical deferasirox formulation
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
US9988452B2 (en) 2014-10-14 2018-06-05 Novartis Ag Antibody molecules to PD-L1 and uses thereof
US20170340733A1 (en) 2014-12-19 2017-11-30 Novartis Ag Combination therapies
KR20160088965A (ko) 2015-01-16 2016-07-27 대원제약주식회사 데페라시록스를 함유하는 현탁제
BR112017018908A2 (pt) 2015-03-10 2018-04-17 Aduro Biotech, Inc. composições e métodos para ativar a sinalização dependente do "estimulador do gene de interferon
CN104817538A (zh) * 2015-03-13 2015-08-05 东南大学 去铁斯诺-他克林金属离子鳌合剂及其药物用途
WO2016167729A1 (en) 2015-04-16 2016-10-20 Öğün Yusuf Toktamiş Dispersible tablets comprising deferasirox
EP3095443A1 (en) 2015-05-21 2016-11-23 Abdi Ibrahim Ilac Sanayi ve Ticaret A.S. Pharmaceutical composition comprising deferasirox
WO2016203488A1 (en) * 2015-06-16 2016-12-22 Havaldar Freddy H Preparation of novel deferasirox analogues for antimalarial activity
EP3964528A1 (en) 2015-07-29 2022-03-09 Novartis AG Combination therapies comprising antibody molecules to lag-3
US20180207273A1 (en) 2015-07-29 2018-07-26 Novartis Ag Combination therapies comprising antibody molecules to tim-3
CN108025051B (zh) 2015-07-29 2021-12-24 诺华股份有限公司 包含抗pd-1抗体分子的联合疗法
KR101695970B1 (ko) * 2015-07-31 2017-01-13 건일제약 주식회사 데페라시록스 함유 산제 및 그 제조방법
CN106554770B (zh) * 2015-09-29 2018-10-19 杭州杜易科技有限公司 一种三唑衍生物金属离子荧光探针及其制备方法和应用
CN108290878B (zh) 2015-10-23 2022-04-26 威佛（国际）股份公司 新的膜铁转运蛋白抑制剂
WO2017106656A1 (en) 2015-12-17 2017-06-22 Novartis Ag Antibody molecules to pd-1 and uses thereof
US20190091204A1 (en) 2016-03-17 2019-03-28 Lupin Limited Compositions of deferasirox
WO2018009466A1 (en) 2016-07-05 2018-01-11 Aduro Biotech, Inc. Locked nucleic acid cyclic dinucleotide compounds and uses thereof
WO2018059922A1 (en) 2016-09-30 2018-04-05 Synthon B.V. Pharmaceutical composition comprising deferasirox
JOP20180036A1 (ar) 2017-04-18 2019-01-30 Vifor Int Ag أملاح لمثبطات فروبورتين جديدة
UY37695A (es) 2017-04-28 2018-11-30 Novartis Ag Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
CZ2017255A3 (cs) 2017-05-04 2018-11-14 Zentiva, K.S. Filmem potažené tablety Deferasiroxu
WO2018208242A1 (en) 2017-05-10 2018-11-15 İlko Ilaç Sanayi Ve Ticaret Anonim Şirketi Formulation of deferasirox tablet for oral suspension composition with better processability
US20200172628A1 (en) 2017-06-22 2020-06-04 Novartis Ag Antibody molecules to cd73 and uses thereof
US11331288B2 (en) 2017-09-14 2022-05-17 The Board Of Trustees Of The Leland Stanford Junior University Conditioning irradiated tissue for increasing vascularity
EP3489692A1 (de) 2017-11-28 2019-05-29 Siemens Healthcare Diagnostics Products GmbH Prothrombinzeit-reagenz enthaltend einen eisenchelator
TR201722910A2 (tr) 2017-12-29 2019-07-22 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Deferasi̇roks i̇çeren suda dağilabi̇len tablet formülasyonlari
KR20190110771A (ko) 2018-03-21 2019-10-01 주식회사 한국팜비오 데페라시록스를 함유하는 소형 분산성 정제
CN108727287B (zh) * 2018-05-10 2020-10-27 东南大学 1,2,4-三唑类化合物及其盐和应用
UY38247A (es) 2018-05-30 2019-12-31 Novartis Ag Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
GR1009592B (el) * 2018-07-03 2019-09-11 Φαρματεν Α.Β.Ε.Ε. Φαρμακευτικο σκευασμα που περιλαμβανει εναν χηλικο παραγοντα συμπλεκτικο του σιδηρου και μεθοδος για την παρασκευη αυτου
KR20200113116A (ko) 2019-03-22 2020-10-06 주식회사 한국팜비오 데페라시록스를 포함하는 필름코팅정제
TW202102478A (zh) 2019-04-01 2021-01-16 瑞士商威佛（國際）股份有限公司 新穎的鐵螯合物
JP2022548881A (ja) 2019-09-18 2022-11-22 ノバルティス アーゲー Ｅｎｔｐｄ２抗体、組合せ療法並びに抗体及び組合せ療法を使用する方法
IT202000000922A1 (it) 2020-01-20 2021-07-20 Cage Chemicals S R L Complessi di ferro e relativi sali come agenti di contrasto per MRI
US11155547B1 (en) * 2020-06-18 2021-10-26 Alterity Therapeutics Limited Compounds for and methods of treating diseases
WO2022186809A1 (en) 2021-03-05 2022-09-09 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi The film coated tablet comprising deferasirox
CN114276305B (zh) * 2021-12-28 2023-11-17 中山大学 一种三取代苯基-1,2,4-三氮唑衍生物及其制备和治疗神经元损伤的应用
CN114591254B (zh) * 2022-03-31 2023-10-13 中山大学 一种3,5-二取代苯基-1,2,4-三氮唑衍生物及其制备方法和应用
CN114478410B (zh) * 2022-03-31 2022-11-29 中山大学 一种二取代苯基-1,2,4-三氮唑衍生物及其制备和应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH388252A (de) 1963-01-24 1964-11-14 Geigy Ag J R Verfahren zum Schützen von Textilmaterial gegen Lichtschädigung
DE2628152C2 (de) 1976-06-23 1985-03-28 Bayer Ag, 5090 Leverkusen Fungizide und nematizide Mittel
US4528196A (en) * 1981-02-23 1985-07-09 The United States Of America As Represented By The Department Of Health And Human Services Chelating agents for the treatment of iron overload
SU1280851A1 (ru) * 1983-07-08 1996-05-27 Ростовский государственный университет 1-фенил-3-алкил-5-(o-оксифенил)-1,2,4-триазолы, обладающие транквилизирующим и антигипоксическим действием, и 1-фенил-3-н-бутил-5-(о-оксифенил)-1,2,4-триазол, обладающий транквилизирующим, антигипоксическим и анальгетическим действием
GB8429307D0 (en) 1984-11-20 1984-12-27 Shell Int Research Heterocyclic herbicides
IL84331A0 (en) * 1987-11-02 1988-04-29 Yissum Res Dev Co Pyridoxyl hydrazone derivatives and pharmaceutical compositions containing the same
US5260322A (en) 1990-10-08 1993-11-09 Merck & Co., Inc. Angiotension II antagonists in the treatment of hyperuricemia
DE4320801A1 (de) * 1993-06-23 1995-01-05 Fahlberg List Pharma Gmbh 2-Hydroxyphenylsubstituierte 1,2,4-Triazole und 1,2,4-Oxadiazole, ihre Verwendung als pharmazeutische Wirkstoffe und sie enthaltende Arzneimittel

Also Published As

Publication number Publication date
HUP9903111A2 (hu) 2000-01-28
NO2018014I2 (no) 2018-11-19
GEP20084355B (forum.php) 2008-04-29
MY129541A (en) 2007-04-30
KR100616378B1 (ko) 2006-08-28
LTPA2007001I1 (lt) 2018-06-25
NO986024L (no) 1998-12-21
CN1146415C (zh) 2004-04-21
IL127212A0 (en) 1999-09-22
TW533205B (en) 2003-05-21
JP3541042B2 (ja) 2004-07-07
KR20050098029A (ko) 2005-10-10
AU718037B2 (en) 2000-04-06
US20030203954A1 (en) 2003-10-30
HK1020530A1 (en) 2000-05-12
NL300248I2 (nl) 2007-03-01
DE122007000020I2 (de) 2010-12-30
CZ291470B6 (cs) 2003-03-12
FR06C0049I2 (fr) 2007-04-27
PT914118E (pt) 2003-02-28
FR06C0049I1 (forum.php) 2007-03-09
CY2007005I1 (el) 2010-07-28
US20030069273A1 (en) 2003-04-10
BG64248B1 (bg) 2004-07-30
EP0914118A1 (en) 1999-05-12
CZ427298A3 (cs) 1999-03-17
CN1223579A (zh) 1999-07-21
JP2000507601A (ja) 2000-06-20
US6723742B2 (en) 2004-04-20
CY2007005I2 (el) 2018-12-12
ATE226435T1 (de) 2002-11-15
LU91291I2 (fr) 2007-01-29
CA2255951A1 (en) 1997-12-31
AR007479A1 (es) 1999-10-27
DE69716602T2 (de) 2003-06-26
AU3262997A (en) 1998-01-14
NO2006017I2 (no) 2011-07-04
US6596750B2 (en) 2003-07-22
DE122007000020I1 (de) 2007-05-24
CA2255951C (en) 2006-10-10
TR199802693T2 (xx) 1999-05-21
NO317180B1 (no) 2004-09-06
SK178598A3 (en) 1999-06-11
NZ333308A (en) 2000-05-26
LU91291I9 (forum.php) 2018-12-27
SI0914118T1 (en) 2003-04-30
PL194758B1 (pl) 2007-07-31
BG103003A (en) 1999-09-30
PL330119A1 (en) 1999-04-26
AP9801407A0 (en) 1998-12-31
WO1997049395A1 (en) 1997-12-31
NL300248I1 (nl) 2007-02-01
SK284319B6 (sk) 2005-01-03
HUP9903111A3 (en) 2000-06-28
NO986024D0 (no) 1998-12-21
ES2187785T3 (es) 2003-06-16
CY2429B1 (en) 2004-11-12
US6465504B1 (en) 2002-10-15
NO2018014I1 (no) 2018-04-17
NO2006017I1 (no) 2006-12-18
BR9709973A (pt) 1999-08-10
RU2208010C2 (ru) 2003-07-10
DK0914118T3 (da) 2003-02-24
AP1127A (en) 2002-12-06
HU226232B1 (en) 2008-07-28
DE69716602D1 (de) 2002-11-28
OA10946A (en) 2003-02-27
EP0914118B1 (en) 2002-10-23

Similar Documents

Publication Publication Date Title
LTPA2007001I1 (lt) Pakeistieji 3,5-difenil-1,2,4-triazolai ir jų panaudojimas farmaciniais metalų chelatoriais
EP0831800A4 (en) ARYLSULFONYLAMINOBENZENE DERIVATIVES AND THEIR USE AS FACTOR Xa INHIBITORS
IL128800A0 (en) 4-Heteroylpyrazol derivatives and the use thereof as herbicides
PT915846E (pt) Fenilcetoenois 2-substituidos e 2,5-substituidos
DE69513671D1 (de) Arzneimittel
TR199501305A2 (tr) Heterosiklik bilesikler ve bunlarin hazirlanmasi ve kullanimi
ZA976222B (en) N-(4-aryl-thiazol-2-yl)-sulphonamide derivatives and their use.
HU9600302D0 (en) Herbicidal benzisoxazole and benzisothiazole-derivatives
IS4352A (is) Sordaridín afleiður gegn sveppum
DK1071433T3 (da) 2',2'-difluornucleosider til immunosuppressiv behandling og kombinationspræparater
DE69732024D1 (de) Haarbehandlungsmittel
DK0821692T3 (da) Immunopotenserende inosinmonophosphat-5'-nukleotidasemodstandsdygtige derivater og anvendelser deraf
NO972502D0 (no) 1,4-Diaryl-2-fluor-2-butan-insekticid- og akaricid-midler
TR199501553A2 (tr) Sefem bilesimleri ve bunlarin farmasötik olarak kullanilmasi.
HUP9600730A1 (en) 1,4-tetrazolinone-derivatives and use thereof as herbicides
DE59708501D1 (de) Haarbehandlungsmittel
DE69636837D1 (de) 1,2,4-benzotriazinoxid-formulierungen
ZA953390B (en) Herbicidal hydroxybenzyl-substituted heteroaryl compounds and derivatives thereof
KR960020195U (ko) 원적외선을 이용한 온열치료기
DE59502706D1 (de) Wärmeisolierender körper
ITPN940023A0 (it) Mobile metallico per comunita'
KR950026632U (ko) 개량 롤식 휴지 케이스
NO991123D0 (no) 25-metylen- og 24,25-epoksy-marcfortiner og paraherkamider
UA25337A (uk) Склад для передпосівhої обробки hасіhhя
BR9403390A (pt) Porta-moedas